Smart inhalers track Fasenra's asthma control over full dosing cycle

NCT ID NCT07654842

Not yet recruiting Disease control Sponsor: Endeavor Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosing cycle. The goal is to learn whether Fasenra's effects last the full 8 weeks without needing extra rescue medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: benralizumab (Fasenra) and budesonide-albuterol (AirSupra)
What this could lead to: If successful, this could confirm that Fasenra maintains asthma control throughout the full 8-week period, potentially reducing the need for rescue inhalers.
What could go wrong: This is a small observational study with 40 participants, so results may not apply to everyone. It does not test a new treatment, only monitors existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA EOSINOPHILIC ASTHMA SEVERE ASTHMA SEVERE EOSINOPHILIC ASTHMA

Contacts and locations

Locations

Endeavor Health

Skokie, Illinois, 60077, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.